Overall Survival In 1st-line NSCLC Reaches 15 Months With Erbitux, Merck Serrono Informs
Nov 21st 2008Drug InformationLung Cancer
Data presented today at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology show that patients with non-small cell lung cancer (NSCLC) who were given Erbitux® (cetuximab) in addition to a standard 1st-line platinum-based chemotherapy lived significantly longer than those who received chemotherapy alone.1 This effect was more pronounced in patients treated with Erbitux who developed early acne-like rash, resulting in median overall survival of 15 months.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
